30 July 2025
If you are covering GSK’s latest financial results, please find below a comment from Sheena Berry, healthcare analyst at Quilter Cheviot:
“GSK reported a solid set of results in the second quarter, with overall sales growing by 6%, a fraction better than the market expected. Much of this growth was driven by speciality medicines and vaccines, as it offset weaker performance from general medicines.
“Shingrix, the group’s shingles vaccine, delivered 6% growth, a turnaround after the 7% decline in the first quarter. It has primarily benefitted from a build up of inventory in France, although US sales continue to be impacted by a slowdown in the pace of penetration. The HIV business also delivered strong growth of 12%, as it benefiting from stocking.
“Due to this strong performance in speciality medicines and vaccines, GSK is pointing to the upper end of its full year guidance range as a realistic expectation. Following strong performance from AstraZeneca, GSK has also delivered a robust financial performance. However, there remain some risks in the business too, with focus currently on a drug called Blenrep, a drug for multiple myeloma. The FDA drugs advisory committee panel voted against the approval of Blenrep and we await to hear if the US regulator will approve the drug with the date set for October.”
